Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (442)	6/1/2000 9:01:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3559

Thursday June 1, 8:39 am Eastern Time Company Press Release P&G to Purchase $17 Million of Regeneron Common Stock at $29.75 per Share TARRYTOWN, N.Y.--(BUSINESS WIRE)--June 1, 2000--Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - news) announced that it will sell 573,630 shares of Regeneron common stock to The Procter & Gamble Company (NYSE: PG - news) at a price of $29.75 per share for total proceeds of approximately $17 million. After the sale, Procter & Gamble will own approximately 5.7 million shares of Regeneron stock (equal to about 16% of total shares outstanding). Procter & Gamble also has warrants to purchase an additional 1.45 million shares. The sale of stock is being made pursuant to an agreement that Regeneron and Procter & Gamble entered into in 1997 that grants Regeneron the right to sell $17 million of common stock to Procter & Gamble. The $29.75 price is the same price per share as in Regeneron's public offering of 2.6 million shares of common stock in April 2000. The sale to Procter & Gamble is expected to close in August 2000. Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron's platform technologies include Targeted Genomics(TM), Functionomics(TM), and Designer Protein Therapeutics(TM). Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. This news release discusses historical information and includes forward-looking statements about Regeneron and about its products, programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of drugs and biologics, determinations by regulatory and administrative governmental authorities, competitive factors, technological developments, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement to be canceled or to terminate without any product success, and other material risks. A more complete description of these risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ending December 31, 1999. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise. -0- Additional information about Regeneron and recent news releases are available on Regeneron's Worldwide Web Home Page at www.regeneron.com. Fax copies of news releases can be obtained from Regeneron's News-on-Demand Service by dialing (800) 311-0841. Contact: Murray A. Goldberg Vice President Finance and Administration and CFO Regeneron Pharmaceuticals, Inc. (914) 345-7492